Evidence map›Paper›PMID 29935312›Full record

ReviewSeminars in cancer biology2018

The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer.

Rindert Missiaen, Massimiliano Mazzone, Gabriele Bergers

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in cancer biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Innate Immune Cells in Melanoma: Implications for Immunotherapy.International journal of molecular sciences · 2024
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Rindert MissiaenVIB-Center for Cancer Biology, and KU Leuven, Department of Oncology, 3000 Leuven, Belgium.
Massimiliano MazzoneVIB-Center for Cancer Biology, and KU Leuven, Department of Oncology, 3000 Leuven, Belgium.
Gabriele BergersVIB-Center for Cancer Biology, and KU Leuven, Department of Oncology, 3000 Leuven, Belgium; Department of Neurological Surgery, Brain Tumor Research Center, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94158, USA. Electronic address: gabriele.bergers@kuleuven.vib.be.
VIB-KU Leuven Center for Cancer Biology · BEUniversity of California, San Francisco · US

Funding

Autophagy as a microenvironmental regulator of tumorigenesis and resistanceR01CA188404 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGERS, GABRIELE, DEBNATH, JAYANTA · 2014 to 2018
$2.1M
Inter-regulatory function of immune-modulation and angiogenesis in cancerR01CA201537 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGERS, GABRIELE · 2016 to 2020
$1.7M
European Research Council 773208NCI NIH HHS R01 CA188404NCI NIH HHS R01 CA201537
6 · The paper itself

Abstract

Tumor angiogenesis and escape of immunosurveillance are two cancer hallmarks that are tightly linked and reciprocally regulated by paracrine signaling cues of cell constituents from both compartments. Formation and remodeling of new blood vessels in tumors is abnormal and facilitates immune evasion. In turn, immune cells in the tumor, specifically in context with an acidic and hypoxic environment, can promote neovascularization. Immunotherapy has emerged as a major therapeutic modality in cancer but is often hampered by the low influx of activated cytotoxic T-cells. On the other hand, anti-angiogenic therapy has been shown to transiently normalize the tumor vasculature and enhance infiltration of T lymphocytes, providing a rationale for a combination of these two therapeutic approaches to sustain and improve therapeutic efficacy in cancer. In this review, we discuss how the tumor vasculature facilitates an immunosuppressive phenotype and vice versa how innate and adaptive immune cells regulate angiogenesis during tumor progression. We further highlight recent results of antiangiogenic immunotherapies in experimental models and the clinic to evaluate the concept that targeting both the tumor vessels and immune cells increases the effectiveness in cancer patients.

Indexed as

Angiogenesis InhibitorsAnimalsHumansImmunotherapyNeoplasmsNeovascularization, PathologicT-Lymphocytes, CytotoxicTumor MicroenvironmentAngiogenesis InhibitorsAngiogenesisAntiangiogenic therapyImmunosuppressionImmunotherapy immune checkpoint inhibitorsInnate and adaptive immune cellsMetabolismTumor hypoxia and acidosis

Identifiers

PMID29935312
PMCPMC6548870
OpenAlexW2809485939

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.